Ironwood Pharmaceuticals (IRWD) Superinvestor holders
11 of the superinvestors we track hold Ironwood Pharmaceuticals (IRWD) in their latest 13F filings, $173M in total.
Summary
The largest holder is Alex Denner (Sarissa Capital Management), with $39M, 21.7% of the portfolio.
In their latest quarter: 2 added, 7 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Alex Denner Sarissa Capital Management |
Held | 9,188,635 | $39M | 21.7% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 7,993,226 | $34M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 6,465,921 | $27M | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Trimmed | 5,052,236 | $20M | 0.0% | Q3 2026 |
| Two Sigma Two Sigma Investments |
Trimmed | 4,556,089 | $19M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
Trimmed | 4,290,093 | $18M | 0.0% | Q2 2026 |
| Arrowstreet Capital | Trimmed | 3,017,089 | $13M | 0.0% | Q2 2026 |
| Man Group Man Group plc |
Trimmed | 392,117 | $2M | 0.0% | Q2 2026 |
| Josef Lakonishok LSV Asset Management |
Held | 308,271 | $1M | 0.0% | Q3 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 122,907 | $517,438 | 0.0% | Q2 2026 |
| Chuck Royce Royce Investment Partners |
Added | 25,301 | $100,445 | 0.0% | Q3 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 11 |
| Q1 2026 | 14 |
| Q4 2025 | 12 |
| Q3 2025 | 11 |
| Q2 2025 | 14 |
| Q1 2025 | 15 |
| Q4 2024 | 15 |
| Q3 2024 | 16 |
Questions about Ironwood Pharmaceuticals
Which superinvestors own Ironwood Pharmaceuticals?
11 of the superinvestors we track hold Ironwood Pharmaceuticals (IRWD) in their latest 13F filings, $173M in total. Alex Denner, Jim Simons, Cliff Asness, Acadian, Two Sigma, Paul Marshall.
Who is the largest superinvestor holder of IRWD?
The largest holder is Alex Denner (Sarissa Capital Management), with $39M, 21.7% of the portfolio.
From Ironwood Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.